Hyperoxia for Interstitial Lung Disease
Recruiting0 awards6 criteria
Vancouver, British Columbia
This trial aims to investigate why patients with interstitial lung disease (ILD) experience symptoms like breathlessness and exercise intolerance. The study will look at differences in the leg muscles of ILD patients, assess
Checkpoint Inhibitor
Atezolizumab for Pulmonary Fibrosis
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing atezolizumab, a medicine that boosts the immune system, in people aged 50 to 80 with idiopathic pulmonary fibrosis (IPF). IPF is a lung disease with no current treatments to stop its progression. Atezolizumab may help slow down lung damage by helping the immune system fight the disease.
Popular Filters
Trials for IPF Patients
Polyphenol
EGCG for Pulmonary Fibrosis
Recruiting0 awardsPhase 1
San Francisco, California
This trial is testing EGCG, a compound from green tea, in patients with idiopathic pulmonary fibrosis (IPF). The goal is to see if EGCG can safely reduce lung scarring. EGCG works by blocking harmful signals that cause lung tissue to harden. Epigallocatechin-3-gallate (EGCG) is a polyphenol and a major component of green tea, known for its potent antioxidant, anti-inflammatory, and anti-fibrotic properties.
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 3
Stanford, California
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Xenon MRI for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 2
Durham, North Carolina
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
Trials for PF Patients
Src kinase inhibitor
Saracatinib for Idiopathic Pulmonary Fibrosis
Recruiting0 awardsPhase 1 & 2
Denver, Colorado
This trial tests a new drug for treating idiopathic pulmonary fibrosis (IPF). It aims to block a protein that causes lung scarring, seeking a safer and more effective treatment for this severe lung disease. Originally developed for cancer, this drug is now being explored for its potential to treat IPF by blocking proteins involved in lung scarring.
Phase 3 Trials
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 3
Stanford, California
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Trials With No Placebo
PET/CT Imaging for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing if two different imaging techniques can show evidence of lung inflammation and fibrosis in patients with idiopathic pulmonary fibrosis. The results may help guide future treatment decisions for patients with this condition.
Xenon MRI for Idiopathic Pulmonary Fibrosis
Recruiting1 awardPhase 2
Durham, North Carolina
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
Behavioural Intervention
Yoga for Idiopathic Pulmonary Fibrosis
Recruiting1 award
Seattle, Washington
This trial will investigate if doing yoga exercises made for patients with Idiopathic Pulmonary Fibrosis can improve their quality of life. Participants will be split in half, with one group doing yoga and the
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.